These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 6422358

  • 1. Deprenyl in the treatment of Parkinson's disease. A specific type B monoamine oxidase inhibitor.
    Lieberman AN, Gopinathan G, Neophytides A, Hiesiger E, Nelson J, Walker R, Goodgold A.
    N Y State J Med; 1984 Jan; 84(1):13-6. PubMed ID: 6422358
    [No Abstract] [Full Text] [Related]

  • 2. [Biochemical basis for using selective monoamine oxidase inhibitors in the treatment of Parkinson's disease. Critical contribution].
    Amato L, Nava L, Rizzo M, Piccoli F.
    Riv Neurol; 1985 Jan; 55(1):46-52. PubMed ID: 3927468
    [No Abstract] [Full Text] [Related]

  • 3. R-(-)-deprenyl as a possible protective agent in Parkinson's disease.
    Tetrud JW, Langston JW.
    J Neural Transm Suppl; 1987 Jan; 25():69-79. PubMed ID: 3123606
    [Abstract] [Full Text] [Related]

  • 4. [Deprenyl as a co-adjuvant in the treatment of Parkinson disease].
    Ferrari E, Cacudi N, de Mari M, Iliceto G, Lamberti P.
    Acta Neurol (Napoli); 1986 Aug; 8(4):455-61. PubMed ID: 3096087
    [No Abstract] [Full Text] [Related]

  • 5. R-(-)-deprenyl and parkinsonism.
    Yahr MD.
    J Neural Transm Suppl; 1987 Aug; 25():5-12. PubMed ID: 3123605
    [Abstract] [Full Text] [Related]

  • 6. Deprenyl in Parkinson's disease.
    Lancet; 1982 Sep 25; 2(8300):695-6. PubMed ID: 6126632
    [No Abstract] [Full Text] [Related]

  • 7. The role of MAO-b inhibitors in the treatment of Parkinson's disease.
    Ruggieri S, Stocchi F, Denaro A, Baronti F, Agnoli A.
    J Neural Transm Suppl; 1986 Sep 25; 22():227-33. PubMed ID: 3097257
    [Abstract] [Full Text] [Related]

  • 8. Selegiline for Parkinson's disease.
    Calesnick B.
    Am Fam Physician; 1990 Feb 25; 41(2):589-91. PubMed ID: 2105624
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. (-)Deprenyl in Parkinson's disease: a two-year study in the different evolutive stages.
    Giovannini P, Martignoni E, Piccolo I, Pacchetti C, Grassi MP, Nappi G, Caraceni T.
    J Neural Transm Suppl; 1986 Feb 25; 22():235-46. PubMed ID: 3097258
    [Abstract] [Full Text] [Related]

  • 11. R-(-)-deprenyl as an adjuvant to levodopa in the treatment of Parkinson's disease.
    Rinne UK.
    J Neural Transm Suppl; 1987 Feb 25; 25():149-55. PubMed ID: 3123601
    [Abstract] [Full Text] [Related]

  • 12. Clinical evaluation of selegiline (L-deprenyl) in the long-term L-dopa treatment syndrome.
    Trebini F, Daniele D, Gillio S, Scarzella L.
    Acta Neurol (Napoli); 1985 Oct 25; 7(5):432-9. PubMed ID: 3933283
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Pergolide and selegiline for Parkinson's disease.
    Med Lett Drugs Ther; 1989 Sep 08; 31(800):81-3. PubMed ID: 2505028
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Adjuvant drugs in the treatment of on-off phenomena in Parkinson's disease.
    Csanda E, Tárczy M, Takáts A, Mogyorós I, Köves A, Bihari K.
    Adv Neurol; 1984 Sep 08; 40():549-56. PubMed ID: 6421113
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Deprenyl (selegiline) combined with levodopa and a decarboxylase inhibitor in the treatment of Parkinson's disease.
    Presthus J, Hajba A.
    Acta Neurol Scand Suppl; 1983 Sep 08; 95():127-33. PubMed ID: 6428145
    [Abstract] [Full Text] [Related]

  • 19. Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Parkinson Study Group.
    Ann Neurol; 1998 Mar 08; 43(3):318-25. PubMed ID: 9506548
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.